JP2023541464A - 2-アミノ-3-カルボニルイミダゾピリジン及びピラゾロピリジン化合物 - Google Patents
2-アミノ-3-カルボニルイミダゾピリジン及びピラゾロピリジン化合物 Download PDFInfo
- Publication number
- JP2023541464A JP2023541464A JP2023517408A JP2023517408A JP2023541464A JP 2023541464 A JP2023541464 A JP 2023541464A JP 2023517408 A JP2023517408 A JP 2023517408A JP 2023517408 A JP2023517408 A JP 2023517408A JP 2023541464 A JP2023541464 A JP 2023541464A
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- amino
- imidazo
- methanone
- fluorocyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078372P | 2020-09-15 | 2020-09-15 | |
| US63/078,372 | 2020-09-15 | ||
| PCT/IB2021/058378 WO2022058890A1 (en) | 2020-09-15 | 2021-09-14 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541464A true JP2023541464A (ja) | 2023-10-02 |
| JP2023541464A5 JP2023541464A5 (cg-RX-API-DMAC7.html) | 2024-02-07 |
Family
ID=80739409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517408A Pending JP2023541464A (ja) | 2020-09-15 | 2021-09-14 | 2-アミノ-3-カルボニルイミダゾピリジン及びピラゾロピリジン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11744824B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4214207A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541464A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230067669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116457355B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021342777A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192158A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022058890A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120603826A (zh) * | 2022-12-30 | 2025-09-05 | 广州市联瑞制药有限公司 | 双环类化合物及其制备方法和应用 |
| KR20260114565A (ko) * | 2023-11-15 | 2026-07-22 | 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 | 6,5-융합 헤테로아릴 유도체 및 이의 용도 |
| TW202525805A (zh) * | 2023-12-29 | 2025-07-01 | 大陸商廣州市聯瑞製藥有限公司 | 雙環類化合物及其製備方法和應用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5154583A (en) * | 1974-11-01 | 1976-05-13 | Kyorin Seiyaku Kk | Shinkipirazoro * 1 55a * pirijinjudotaino seizoho |
| JP2009530233A (ja) * | 2006-02-14 | 2009-08-27 | ノバルティス アーゲー | Pi−3キナーゼインヒビターおよびそれらの使用方法 |
| JP2009539851A (ja) * | 2006-06-06 | 2009-11-19 | アビジェン, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
| WO2020056072A1 (en) * | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097483A (en) | 1974-11-01 | 1978-06-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolo 1,5-a!pyridines |
| JP2007529496A (ja) * | 2004-03-19 | 2007-10-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体 |
| KR20080002866A (ko) | 2005-04-25 | 2008-01-04 | 노파르티스 아게 | 펩티드 데포르밀라제 (pdf) 억제제로서 유용한이미다조(1,2-a)피리딘 유도체 |
| CA2825746A1 (en) | 2011-01-26 | 2012-08-02 | Kyorin Pharmaceutical Co. Ltd. | Pyrazolopyridine derivative or pharmacologically acceptable salt thereof |
| US20150158868A1 (en) | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
-
2021
- 2021-09-14 US US17/474,293 patent/US11744824B2/en active Active
- 2021-09-14 AU AU2021342777A patent/AU2021342777A1/en active Pending
- 2021-09-14 JP JP2023517408A patent/JP2023541464A/ja active Pending
- 2021-09-14 CN CN202180063093.0A patent/CN116457355B/zh active Active
- 2021-09-14 KR KR1020237012894A patent/KR20230067669A/ko active Pending
- 2021-09-14 CA CA3192158A patent/CA3192158A1/en active Pending
- 2021-09-14 WO PCT/IB2021/058378 patent/WO2022058890A1/en not_active Ceased
- 2021-09-14 EP EP21868834.9A patent/EP4214207A4/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5154583A (en) * | 1974-11-01 | 1976-05-13 | Kyorin Seiyaku Kk | Shinkipirazoro * 1 55a * pirijinjudotaino seizoho |
| JP2009530233A (ja) * | 2006-02-14 | 2009-08-27 | ノバルティス アーゲー | Pi−3キナーゼインヒビターおよびそれらの使用方法 |
| JP2009539851A (ja) * | 2006-06-06 | 2009-11-19 | アビジェン, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
| WO2020056072A1 (en) * | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Non-Patent Citations (7)
| Title |
|---|
| ARQUES, A. ET AL.: ""The Reaction of 1-Amino-4,6-diphenyl-2-methylthiopyridinium Iodide with Substituted Acetonitriles", SYNTHESIS, vol. 1981, no. 11, JPN7025000275, 1981, pages 910 - 912, ISSN: 0005707570 * |
| BELAROUSSI, R. ET AL.: ""Three successive and regiocontroled palladium cross-coupling reactions to easily synthesize novel", RSC ADVANCES, vol. 8, no. 2, JPN6025003378, 2018, pages 732 - 741, ISSN: 0005707574 * |
| HOU, JUE ET AL.: ""Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of in", CELL DEATH & DISEASE, vol. 10, no. 7, JPN6025003373, 2019, pages 1 - 13, ISSN: 0005707575 * |
| RAUF, ABDUL ET AL.: ""Synthesis, characterization, and urease inhibition of 5-substituted-8-methyl-2H-pyrido[1,2-a]pyrim", MEDICINAL CHEMISTRY RESEARCH, vol. 21, no. 1, JPN6025003376, 2012, pages 60 - 74, ISSN: 0005707573 * |
| REGISTRY(STN)[ONLINE], vol. Entered STN: 13 Feb 2014, JPN7025000276, pages 2024 - 12, ISSN: 0005707571 * |
| REGISTRY(STN)[ONLINE], vol. Entered STN: 19 Jul 2017, JPN7025000274, pages 2024 - 12, ISSN: 0005707569 * |
| SHESTAKOV, ALEXANDER S. ET AL.: ""Detailed Studies of the Alkylation Sides of Pyridin‐2‐yl and 4,6‐Dimethylpyrimidin‐2‐yl‐cyan", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 54, no. 1, JPN6025003374, 2017, pages 551 - 560, ISSN: 0005707572 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4214207A4 (en) | 2024-10-02 |
| CN116457355A (zh) | 2023-07-18 |
| US11744824B2 (en) | 2023-09-05 |
| US20220087985A1 (en) | 2022-03-24 |
| EP4214207A1 (en) | 2023-07-26 |
| WO2022058890A1 (en) | 2022-03-24 |
| AU2021342777A1 (en) | 2023-04-27 |
| CA3192158A1 (en) | 2022-03-24 |
| KR20230067669A (ko) | 2023-05-16 |
| AU2021342777A9 (en) | 2024-05-30 |
| CN116457355B (zh) | 2026-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114867720B (zh) | 杂芳基类衍生物及其制备方法和用途 | |
| CN113454082B (zh) | 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途 | |
| CN108349940B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
| AU2006297948A1 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| EP2181112A1 (en) | Triazolopyridine compounds and their use as ask inhibitors | |
| TW201446758A (zh) | 作爲β-分泌酶抑制劑的全氟化5,6-二氫-4H-1,3-□-2-胺化合物及其用途 | |
| TW201710255A (zh) | 雜環化合物 | |
| WO2012105594A1 (ja) | 縮環複素環誘導体 | |
| CN116457355B (zh) | 2-氨基-3-羰基咪唑并吡啶和吡唑并吡啶化合物 | |
| WO2017000276A1 (en) | Bicyclic heterocyclic compounds as pde2 inhibitors | |
| WO2016183741A1 (en) | Pyrimidinone amide compounds as pde2 inhibitors | |
| EP4200299B1 (en) | Compounds for prevention or treatment of neurodegenerative disorders | |
| US11926632B2 (en) | Methods and compounds for restoring mutant p53 function | |
| HK40096261A (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | |
| RU2833052C2 (ru) | Имидазопиридинильные соединения и их применение для лечения нейродегенеративных расстройств | |
| HK40058868A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | |
| HK40058868B (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260114 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260421 |